insitro is thrilled to announce the appointment of Hideo Makimura, M.D., Ph.D., as Chief Medical Officer, a pivotal step as we advance our therapeutic programs toward the clinic.
"Hideo has spent his career using human genetics and biomarkers to guide and accelerate clinical
The second issue of Deep Phenotype, insitro’s Substack publication on scaled biology and deep causality, is now live. In “Mapping Causal Human Biology: From Outcome to Mechanism,” insitro CEO and founder @DaphneKoller examines the problem at the center of drug discovery – moving
insitro founder and CEO @DaphneKoller recently stopped by The Information Bottleneck podcast to chat with hosts @ziv_ravid and @Hellisotherpe10 about causal biology and why AI in drug discovery is a fundamentally different problem than AI in language or vision. The conversation
Exciting day at insitro with the launch of Deep Phenotype, our new Substack publication covering scaled biology and deep causality.
Over the coming months, we'll separate truth from hype as we explore causal human biology, physical AI, and the work of turning discovery into
If you feed an LLM just a few of @insitro founder and CEO @DaphneKoller’s accomplishments at the frontiers of artificial intelligence and machine learning, it will tell you what we already know:
"The through line is the belief that if we can represent uncertainty correctly,
